Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohortResearch in context

Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohortResearch in context

Summary: Background: A safe and highly efficacious Escherichia coli-produced HPV-16/18 bivalent vaccine (Cecolin®) offers a cost-effective cervical cancer prevention measure. Here, we report data on the long-term efficacy and immunopersistence up to 10 years post-vaccination. Methods: In the Phase...

Full description

Saved in:
Bibliographic Details
Main Authors: Fanghui Zhao, Qi Chen, Chao Zhao, Lingling Nie, Shangying Hu, Jian Yin, Lingxian Qiu, Zhaofeng Bi, Jiali Quan, Yufei Li, Mingzhu Li, Xun Zhang, Qinjing Pan, Caihong Li, Lidong Ke, Xiaoli Liu, Fengxian Zheng, Cuihong Dai, Zhe Wang, Xuefeng Kuang, Xinhua Jia, Yingying Su, Shoujie Huang, Qiufen Zhang, Weijin Huang, Lihui Wei, Jun Zhang, Ting Wu, Youlin Qiao, Ningshao Xia
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:The Lancet Regional Health. Western Pacific
Subjects:
Human papillomavirus vaccine
Escherichia coli
Long-term efficacy
Immunopersistence
Online Access:http://www.sciencedirect.com/science/article/pii/S266660652500207X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S266660652500207X

Similar Items